Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Operating Grant - PA: HIV/AIDS Research Initiative - Biomedical/Clinical Stream

University of Toronto

$133,511.00

T Cell Immunity in HIV-1/HCV Co-infection

FY 2008-09

Summary
Approximately 25% of persons infected with human immunodeficiency virus 1 (HIV-1) are also infected with the hepatitis C virus (HCV) which is a major cause of cirrhosis (scarring) of the liver and liver cancer. Persons co-infected with both HIV-1 and HCV have at least a 6 fold risk of progression to liver cirrhosis, when compared to HCV infected, but HIV-1 uninfected individuals. It is currently unknown why having infection with HIV-1 makes HCV much worse. About one in five persons with HCV/HIV-1 infection will only respond to the treatment for the HCV, which is a one year treatment. Thus, studies are urgently needed to understand this dual infection. The present study will use state of the art technologies in immunology in order to determine why HCV gets worse in the presence of HIV-1. One possibility is that the AIDS virus increases the amount of immune damage to the liver accidentally in dual infected persons. Another possibility is that the AIDS virus 'confuses' the immune system when it fights HCV. All of these possibilities will be answered in the current study. The results of this study will have important impact on understanding how HIV/HCV co-infection impacts liver disease and will influence how to treat persons co-infected with both HIV-1 and HCV. In addition the study will yield useful information for those involved with developing new immunologic treatments against HIV and HCV.
Program
Operating Grant - PA: HIV/AIDS Research Initiative - Biomedical/Clinical Stream
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
177304
Name
Ostrowski Mario A
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Infection and Immunity
Theme2
Biomedical
Prcname2
Virology & Viral Pathogenesis
Projecttitle
T Cell Immunity in HIV-1/HCV Co-infection
Programtype2
Operating Grants
Orgnameinp2
University of Toronto
Cihramount2
$133,511
Cihrequipment2
$0
Programname2
Operating Grant - PA: HIV/AIDS Research Initiative - Biomedical/Clinical Stream
Keyworddelim
Cirrhosis; Cross-Reactive Immunity; Hepatitis C Virus (Hcv); Hiv; Inflammation; T Cells
Abstract
Approximately 25% of persons infected with human immunodeficiency virus 1 (HIV-1) are also infected with the hepatitis C virus (HCV) which is a major cause of cirrhosis (scarring) of the liver and liver cancer. Persons co-infected with both HIV-1 and HCV have at least a 6 fold risk of progression to liver cirrhosis, when compared to HCV infected, but HIV-1 uninfected individuals. It is currently unknown why having infection with HIV-1 makes HCV much worse. About one in five persons with HCV/HIV-1 infection will only respond to the treatment for the HCV, which is a one year treatment. Thus, studies are urgently needed to understand this dual infection. The present study will use state of the art technologies in immunology in order to determine why HCV gets worse in the presence of HIV-1. One possibility is that the AIDS virus increases the amount of immune damage to the liver accidentally in dual infected persons. Another possibility is that the AIDS virus 'confuses' the immune system when it fights HCV. All of these possibilities will be answered in the current study. The results of this study will have important impact on understanding how HIV/HCV co-infection impacts liver disease and will influence how to treat persons co-infected with both HIV-1 and HCV. In addition the study will yield useful information for those involved with developing new immunologic treatments against HIV and HCV.
Competitiondate
200809
Approvedterm2
2 yrs 0 mth
Pinamesdelim
Ostrowski, Mario A
Approvedterm
2 ans 0 mois
Cihrcontribution2
~ $133,511~ $0~
University of Toronto - $133,511 Grant (2008-09) | Canada Spends